CREB1 and non-small cell lung carcinoma: Taken together, our results demonstrate that targeting CREB sensitizes cisplatin-resistant NSCLC cells to cisplatin, suggesting that CREB inhibition combined with cisplatin is a potential strategy to overcome cisplatin resistance.